Charles Schwab Investment Management Inc. Sells 289,312 Shares of Invivyd, Inc. (NASDAQ:IVVD)

Charles Schwab Investment Management Inc. decreased its holdings in shares of Invivyd, Inc. (NASDAQ:IVVD) by 57.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 210,749 shares of the company’s stock after selling 289,312 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.18% of Invivyd worth $215,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the stock. Proficio Capital Partners LLC purchased a new position in shares of Invivyd in the third quarter valued at $27,000. Cubist Systematic Strategies LLC grew its holdings in Invivyd by 66.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after buying an additional 53,499 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in shares of Invivyd during the second quarter valued at about $115,000. Dimension Capital Management LLC lifted its holdings in shares of Invivyd by 243.3% in the second quarter. Dimension Capital Management LLC now owns 189,871 shares of the company’s stock worth $209,000 after buying an additional 134,571 shares in the last quarter. Finally, Duquesne Family Office LLC bought a new position in shares of Invivyd in the second quarter valued at approximately $629,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Invivyd Stock Performance

Shares of NASDAQ:IVVD opened at $0.43 on Friday. The firm has a market capitalization of $51.40 million, a PE ratio of -0.22 and a beta of 0.53. Invivyd, Inc. has a 52-week low of $0.43 and a 52-week high of $5.20. The firm has a fifty day moving average of $0.79 and a 200 day moving average of $1.03.

Insider Transactions at Invivyd

In other news, Director Terrance Mcguire sold 160,400 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $0.59, for a total value of $94,636.00. Following the completion of the sale, the director now directly owns 4,202,679 shares in the company, valued at approximately $2,479,580.61. The trade was a 3.68 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last three months, insiders sold 450,523 shares of company stock worth $251,994. 17.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms recently weighed in on IVVD. EF Hutton Acquisition Co. I raised shares of Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. HC Wainwright lowered their price objective on Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. Morgan Stanley reduced their target price on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research report on Wednesday, November 20th. Finally, D. Boral Capital reiterated a “buy” rating and set a $9.00 price target on shares of Invivyd in a research report on Thursday, November 21st. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Invivyd currently has an average rating of “Buy” and a consensus target price of $7.89.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.